Chris Schott
Stock Analyst at JP Morgan
(4.08)
# 541
Out of 5,133 analysts
151
Total ratings
65.38%
Success rate
8.2%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $32.47 | +7.79% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $15.06 | +19.52% | 14 | Dec 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,150 | $1,077.19 | +6.76% | 23 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $8.43 | +42.35% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $124.62 | +60.49% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $714.04 | +8.54% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $220.75 | +17.78% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $121.76 | +23.19% | 8 | Oct 31, 2025 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $24.45 | -1.84% | 4 | Oct 7, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $12.97 | +7.94% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $950 → $800 | $758.91 | +5.41% | 8 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $178.30 | -1.85% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $40.36 | +4.06% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $324.30 | -16.74% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $25.15 | +35.19% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $108.26 | +15.46% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $13.37 | +4.71% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.70 | +547.06% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.50 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $55.92 | +39.48% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.61 | +155,867.82% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.10 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $21.59 | +131.59% | 3 | Nov 2, 2018 |
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $32.47
Upside: +7.79%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $15.06
Upside: +19.52%
Eli Lilly and Company
Nov 18, 2025
Maintains: Overweight
Price Target: $1,050 → $1,150
Current: $1,077.19
Upside: +6.76%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $8.43
Upside: +42.35%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $124.62
Upside: +60.49%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $714.04
Upside: +8.54%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $220.75
Upside: +17.78%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $121.76
Upside: +23.19%
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $24.45
Upside: -1.84%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $12.97
Upside: +7.94%
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $758.91
Upside: +5.41%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $178.30
Upside: -1.85%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $40.36
Upside: +4.06%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $324.30
Upside: -16.74%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $25.15
Upside: +35.19%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $108.26
Upside: +15.46%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $13.37
Upside: +4.71%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.70
Upside: +547.06%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.50
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $55.92
Upside: +39.48%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.61
Upside: +155,867.82%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.10
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $21.59
Upside: +131.59%